Ally Bridge Group (NY) LLC reported 18 holdings worth US$76M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Ally Bridge Group (NY) LLC reported 18 holdings worth US$76M as of Sep 30, 2026. Largest: Edgewise Therapeutics, Inc., ProMIS Neurosciences Inc. and Minerva Neurosciences, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 18
- Value as reported
- US$76M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Edgewise Therapeutics, Inc. | 185K | US$7.53M | 9.9% |
| ProMIS Neurosciences Inc. | 620K | US$6.73M | 8.9% |
| Minerva Neurosciences, Inc | 1.66M | US$5.55M | 7.3% |
| Amylyx Pharmaceuticals, Inc. | 182K | US$5.3M | 7.0% |
| Shattuck Labs, Inc. | 625K | US$4.26M | 5.6% |
| Obsidian Therapeutics, Inc. | 302K | US$4.15M | 5.5% |
| AN2 Therapeutics, Inc. | 526K | US$2.8M | 3.7% |
| Eupraxia Pharmaceuticals, Inc. | 231K | US$2.1M | 2.8% |
| Avalo Therapeutics, Inc. | 134K | US$2.06M | 2.7% |
| Inventiva SA | 227K | US$839K | 1.1% |
| Vogenx Inc | 32,701 | US$745K | 0.98% |
| Traws Pharma, Inc. | 786K | US$467K | 0.61% |
| Perspective Therapeutics, Inc. | 164K | US$450K | 0.59% |
| Assembly Biosciences, Inc. | 18,298 | US$430K | 0.57% |
| Climb Bio, Inc. | 0 | US$0 | 0.00% |
| CytomX Therapeutics, Inc. | 0 | US$0 | 0.00% |
| First Tracks Biotherapeutics, Inc. | 0 | US$0 | 0.00% |
| iBio, Inc. | 0 | US$0 | 0.00% |
| IDEAYA Biosciences, Inc. | 0 | US$0 | 0.00% |
| Kura Oncology, Inc. | 0 | US$0 | 0.00% |
| Ovid Therapeutics Inc. | 0 | US$0 | 0.00% |
| Palisade Bio, Inc. | 0 | US$0 | 0.00% |
| Solid Biosciences Inc. | 0 | US$0 | 0.00% |
| Whitehawk Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Alumis Inc. | 0 | US$0 | 0.00% |
| Axsome Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC